Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

A case of fatal Rosai-Dorfman syndrome in an adult; failure of multiple empiric therapies.

Antic N, Ultmann JE, Dragovich T.

J BUON. 2006 Jul-Sep;11(3):351-3. No abstract available.

PMID:
17309162
2.

One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress?

Ultmann JE, Ong ST, Stupp R.

Ann Oncol. 1997;8 Suppl 1:1-3. Review. No abstract available.

PMID:
9187420
3.

Western impressions of the Hong Kong health care system.

Bennett CL, Pei GK, Ultmann JE.

West J Med. 1996 Jul-Aug;165(1-2):37-42.

4.

The cost-benefit ratio of the cure of Hodgkin's disease.

Ultmann JE, Ong ST.

Cancer J Sci Am. 1995 May-Jun;1(1):23-5. No abstract available.

PMID:
9166448
5.

Levitt.

Ultmann JE.

Pharos Alpha Omega Alpha Honor Med Soc. 1995 Winter;58(1):32-3. No abstract available.

PMID:
7886139
6.

Management of lymphoma in the 1990s: introduction to the proceedings of the Fifth International Conference on Malignant Lymphoma.

Stupp R, Samuels BL, Ultmann JE.

Ann Oncol. 1994;5 Suppl 2:1-3. No abstract available.

PMID:
8204509
7.

The Lugano International Conferences on Malignant Lymphoma, 1981-1993.

Samuels BL, Stupp R, Ultmann JE.

Ann Oncol. 1994;5 Suppl 1:1-4. No abstract available.

PMID:
8172805
8.

Malignancies of undetermined primary origin.

Bitran JD, Ultmann JE.

Dis Mon. 1992 Apr;38(4):213-60. Review.

PMID:
1547698
9.

Classification of Hodgkin's disease: yesterday, today and tomorrow.

Ultmann JE.

Eur J Cancer. 1992;28A(12):2074-9. Review. No abstract available.

PMID:
1419305
10.

Malignant effusions.

Olopade OI, Ultmann JE.

CA Cancer J Clin. 1991 May-Jun;41(3):166-79. Review. No abstract available.

11.

The Fourth International Conference on Malignant Lymphoma.

Samuels BL, Ultmann JE.

Ann Oncol. 1991 Feb;2 Suppl 2:1-7. No abstract available.

PMID:
1675580
12.

Funding for cancer research.

Ultmann JE, Donoghue M, Lierman TL.

Cancer Invest. 1991;9(6):707-9. No abstract available.

PMID:
1747797
13.

Cancer of unknown primary site.

Ultmann JE.

J Cancer Res Clin Oncol. 1991;117(6):505-9. No abstract available.

PMID:
1744156
14.

Pseudo deep-vein thrombosis following desferrioxamine infusion: a previously unreported adverse reaction?

Jacobs P, Wood L, Bird AR, Ultmann JE.

Lancet. 1990 Sep 29;336(8718):815. No abstract available.

PMID:
1976177
15.

Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP.

Olopade OI, Larson RA, Mick R, Watson SM, Hoffman PC, Ultmann JE, Golomb HM.

Leukemia. 1990 Feb;4(2):127-31.

PMID:
1689439
16.

Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy.

Farah R, Golomb HM, Hallahan DE, Desser RK, Griem ML, Blough R, Ultmann JE, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):761-6.

PMID:
2777665
17.

The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone.

Hallahan DE, Farah R, Vokes EE, Bitran JD, Ultmann JE, Golomb HM, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):767-71.

PMID:
2674082
18.

Current recommendations for the staging and restaging of lymphoma.

Ultmann JE, Bitran JD.

Curr Opin Oncol. 1989 Oct;1(1):17-22. Review. No abstract available.

PMID:
2489944
19.

Lymphomas--current progress and future directions.

Samuels BL, Ultmann JE.

Perspect Biol Med. 1989 Summer;32(4):513-25. Review. No abstract available.

PMID:
2674886
20.
21.

A fight worth fighting: reflections on the National Cancer Program.

Ultmann JE.

Cancer Invest. 1988;6(3):357-60. No abstract available.

PMID:
3167615
22.

The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas.

Williams SF, Schilsky RL, Ultmann JE, Samuels BL.

Cancer Invest. 1988;6(4):427-37. Review.

PMID:
3052703
23.

Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma.

Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlock C, Myers JW, Kisner D, Norred S, Spiegel RJ, Bonnem EM.

Semin Oncol. 1987 Jun;14(2 Suppl 2):18-23. No abstract available.

PMID:
3589702
24.

Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.

Schilsky RL, Williams SF, Ultmann JE, Watson S.

J Clin Oncol. 1987 Mar;5(3):419-25.

PMID:
3819808
25.

Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.

Williams SF, Ultmann JE, Gaynor E, Watson S.

Cancer Treat Rep. 1986 Aug;70(8):1033-4. No abstract available.

PMID:
2425964
26.

Thyroid lymphoma in a patient with hyperthyroidism.

Ultmann JE.

Am J Med. 1985 Dec;79(6):A42. No abstract available.

PMID:
4073104
28.

Pneumonia as a sequela of immunosuppression. Differential diagnosis.

Gaynor ER, Ultmann JE.

Hosp Pract (Off Ed). 1985 Oct 15;20(10):74A-74C, 74H-74J, 74L passim. No abstract available.

PMID:
3930544
29.

Long-term survival of patients with localized diffuse histiocytic lymphoma.

Vokes EE, Ultmann JE, Golomb HM, Gaynor ER, Ferguson DJ, Griem ML, Oleske D.

J Clin Oncol. 1985 Oct;3(10):1309-17.

PMID:
3900300
30.

Pathologic stages IA and IIA Hodgkin's disease: results of treatment with radiotherapy alone (1968-1980).

Cornbleet MA, Vitolo U, Ultmann JE, Golomb HM, Oleske D, Griem ML, Ferguson DJ, Miller JB.

J Clin Oncol. 1985 Jun;3(6):758-68.

PMID:
4009215
31.

The non-Hodgkin's lymphomas.

Ultmann JE, Jacobs RH.

CA Cancer J Clin. 1985 Mar-Apr;35(2):66-87. No abstract available.

32.

Non-Hodgkin's lymphoma: management strategies.

Gaynor ER, Ultmann JE.

N Engl J Med. 1984 Dec 6;311(23):1506-8. No abstract available.

PMID:
6504074
33.

Neurocrest and colonic tumors: new clinical syndrome. Report of three cases.

Wade JL 3rd, Tobin E, Ultmann JE.

Am J Med. 1984 Oct;77(4):725-8.

PMID:
6486148
34.

Diffuse immunoblastic sarcoma from benign lymphoid proliferation.

Wade JL 3rd, Taylor JR, Ultmann JE.

Ann Intern Med. 1984 May;100(5):765. No abstract available.

PMID:
6608894
35.
36.

Histiocytic lymphoma: response to chemotherapy.

Bitran JD, Sweet DL, Vardiman J, Golomb HM, Ultmann JE.

Ann Intern Med. 1982 Oct;97(4):617-8. No abstract available.

PMID:
6751185
37.

Cure of histiocytic lymphoma.

Ultmann JE.

Ann Intern Med. 1982 Aug;97(2):274-5. No abstract available.

PMID:
7049035
38.

Prognostic significance of the Lukes and Collins classification in patient treated with COMLA.

Sweet DL, Collins RD, Stein RS, Ultmann JE.

Cancer Treat Rep. 1982 May;66(5):1107-11.

PMID:
7044531
39.

The strategic role of laparotomy in staging Hodgkin's disease.

Larson RA, Ultmann JE.

Cancer Treat Rep. 1982 Apr;66(4):767-74. No abstract available.

PMID:
7074647
40.

Anatomic substages of stage IIIA Hodgkin's disease: followup of a collaborative study.

Stein RS, Golomb HM, Wiernik PH, Mauch P, Hellman S, Ultmann JE, Rosenthal DS, Flexner JM.

Cancer Treat Rep. 1982 Apr;66(4):733-41.

PMID:
7074643
41.

Survival of patients with localized diffuse histiocytic lymphoma.

Sweet DL, Kinzie J, Gaeke ME, Golomb HM, Ferguson DL, Ultmann JE.

Blood. 1981 Dec;58(6):1218-23.

42.

Multiple histologic subtypes of non-Hodgkin's lymphoma: clinical and pathologic features.

Leyser S, Variakojis D, Mintz U, Vardiman JW, Ultmann JE.

Cancer. 1981 Nov 1;48(9):2063-9.

PMID:
7296513
43.

[The current state of curability of Hodgkin's disease].

Streuli RA, Ultmann JE.

Schweiz Med Wochenschr. 1981 Sep 5;111(36):1301-3. German.

PMID:
7302531
44.

Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction.

Miller JB, Variakojis D, Bitran JD, Sweet DL, Kinzie JJ, Golomb HM, Ultmann JE.

Cancer. 1981 Feb 15;47(4):748-56.

PMID:
6784911
45.

Late relapses in Hodgkin disease.

Kanofsky JR, Golomb HM, Vardiman JE, Sweet DL, Ultmann JE.

Am J Hematol. 1981;10(1):31-6.

PMID:
7258180
46.

Non-Hodgkin's lymphomas: historical perspective and future prospects.

Streuli RA, Ultmann JE.

Semin Oncol. 1980 Sep;7(3):223-33. Review. No abstract available.

PMID:
6998001
47.

Importance of substaging of stage III Hodgkin's disease.

Golomb HM, Sweet DL, Ultmann JE, Miller JB, Kinzie JJ, Gordon LI.

Semin Oncol. 1980 Jun;7(2):136-43. No abstract available.

PMID:
7444470
48.

Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma.

Sweet DL, Golomb HM, Ultmann JE, Miller JB, Stein RS, Lester EP, Mintz U, Bitran JD, Streuli RA, Daly K, Roth NO.

Ann Intern Med. 1980 Jun;92(6):785-90.

PMID:
6992679
49.

The cure of disseminated Hodgkin's disease: prospects and problems.

Streuli RA, Ultmann JE.

Ann Intern Med. 1980 May;92(5):693-5. No abstract available.

PMID:
7387012
50.

Anatomic substages of stage III-A Hodgkin's disease. A collaborative study.

Stein RS, Golomb HM, Diggs CH, Mauch P, Hellman S, Wiernik PH, Ultmann JE, Rosenthal DS.

Ann Intern Med. 1980 Feb;92(2 Pt 1):159-65.

PMID:
7352720

Supplemental Content

Loading ...
Support Center